Skip to main content

Table 3 Clinical adverse reactions of group A and group B patients

From: Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis

Group

Group A (34)

Group B (34)

P

Leukopenia

3(8.82)

3(8.82)

0.086

Nausea and vomiting

2(5.88)

2(5.88)

1.000

Liver and kidney dysfunction

2(5.88)

1(2.94)

0.555

Allergic reaction

1(2.94)

0(0.00)

0.314

Gastrointestinal tract reaction

2(5.88)

1(2.94)

0.555

Alopecia

3(8.82)

3(8.82)

1.000

Abdominal pain

2(5.88)

2(5.88)

1.000

Total adverse reactions [n(%)]

15(44.12)

13(38.24)

0.622